Tandem Diabetes Care, Inc. (0M0F.L)
| Previous close | 38.20 |
| Open | 40.17 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 40.17 - 40.17 |
| 52-week range | 40.17 - 40.17 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 22.74M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | 4.51 |
| EPS (TTM) | 0.09 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
- Business Wire
Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology
SAN DIEGO, March 15, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range* in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology** compared to those on a standard insulin pump
